Carlotta A Powell, ADC,CS,PRSS | |
7000 N Stateline Ave, Texarkana, AR 71854 | |
(870) 774-1315 | |
Not Available |
Full Name | Carlotta A Powell |
---|---|
Gender | Female |
Speciality | Peer Specialist |
Location | 7000 N Stateline Ave, Texarkana, Arkansas |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1023500634 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YA0400X | Counselor - Addiction (substance Use Disorder) | (* (Not Available)) | Secondary |
175T00000X | Peer Specialist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Carlotta A Powell, ADC,CS,PRSS 2904 Arkansas Blvd, Texarkana, AR 71854-2536 Ph: (870) 773-4655 | Carlotta A Powell, ADC,CS,PRSS 7000 N Stateline Ave, Texarkana, AR 71854 Ph: (870) 774-1315 |
News Archive
The pineal gland - integral to setting the body's sleep and wake cycles - may be involved in a broad range of bodily functions, according to a study by researchers at the National Institutes of Health and other institutions.
The Senate Appropriations Committee on Thursday voted 26-3 to approve a $152 billion fiscal year 2008 Labor-HHS-Education appropriations bill after the addition of an amendment that would expand federal funding for embryonic stem cell research, CongressDaily reports (Cohn, CongressDaily, 6/22).
Seaside Therapeutics LLC today announced the issuance of U.S. patent 7,648,993 B2 (‘993 patent), which covers methods of treating autism with group 1 antagonists of the metabotropic glutamate receptor (mGluR) pathway. An earlier related patent, U.S. patent 6,890,931 B2 (‘931 patent), was issued in 2005 and covers methods of treating Fragile X Syndrome, the most common known cause of autism, with group 1 antagonists of the mGluR pathway.
A study published today in the Archives of Internal Medicine may shed new light on why minority Americans have poorer health outcomes from chronic conditions such as hypertension, heart disease and diabetes.
Roche Diagnostics and CapitalBio have announced their intention to initiate a strategic partnership targeting molecular diagnostic applications and the development of technologies to fill the unmet needs of researchers worldwide. This new development builds on the genomics and diagnostics expertise of the two companies and will focus on furthering microarray technologies and complementary products for molecular diagnostic applications.
› Verified 5 days ago